Connect with us

Science

‘Strong evidence’ for cannabis as treatment for Alzheimer’s, says review

Several phytocannabinoids, terpenes and flavonoids demonstrated neuroprotective properties.

Published

on

'Strong evidence' for cannabis as treatment for Alzheimer's, says review
Around 55 million people around the world are thought to be living with dementia.

A new review has found ‘strong evidence’ for the role of cannabis in the treatment of  Alzheimer’s disease.

Researchers examining existing preclinical studies say there is ‘strong evidence’ to support the idea that cannabinoids have neuroprotective properties and could have a role in treating common neurodegenerative diseases, including Alzheimer’s.

In a review published this month, scientists evaluated the neuroprotective potential of  Cannabis sativa L with a particular focus on its use as a therapeutic for treating dementia and Alzheimer’s disease.

Around 55 million people around the world are thought to be living with dementia, a number that is rising in line with an ageing population.

Alzheimer’s disease,  which causes a decline in cognitive and functional abilities, is a type of dementia which, along with vascular dementia, makes up the majority of cases. It is also the most common neurodegenerative disease globally.

There is currently no cure for Alzheimer’s and existing treatments are focused on symptom management, rather than slowing disease progression. 

Could cannabis offer new hope?

A number of studies have examined medicinal cannabis could be used to treat some of the symptoms of the disease, such as easing aggression, agitation and anxiety, which are commonly seen among patients. 

Furthermore, the cannabinoids CBD, THC and CBN [cannabinol], have been highlighted as potentially having neuroprotective properties, preventing cell death and damage in the brain, although more research is needed.

Now researchers have analysed a number of in vitro and in vivo, preclinical studies on the neuroprotective potential of phytochemicals found in the plant.

According to the paper, many of the active compounds in cannabis were evidenced as having efficacy in the treatment of neurodegenerative conditions exemplified by Alzheimer’s disease.

Several phytocannabinoids, terpenes and select flavonoids demonstrated neuroprotection through a ‘myriad of cellular and molecular pathways’, the authors said.

They concluded: “These findings provide strong evidence for a role of cannabis constituents, individually or in combination, as potential neuroprotectants timely to the emergent use of medicinal cannabis as a novel treatment for neurodegenerative diseases.”

They went on to recommend further randomised control trials and clinical studies to try to better understand exactly how these compounds work and substantiate these initial findings.

Home » Science » ‘Strong evidence’ for cannabis as treatment for Alzheimer’s, says review

Sarah Sinclair is a respected cannabis journalist writing on subjects related to science, medicine, research, health and wellness. She is managing editor of Cannabis Health, the UK’s leading title covering medical cannabis and CBD, and sister titles, Cannabis Wealth and Psychedelic Health. Sarah has an NCTJ journalism qualification and an MA in Journalism from the University of Sunderland. Sarah has over six years experience working on newspapers, magazines and digital-first titles, the last two of which have been in the cannabis sector. She has also completed training through the Medical Cannabis Clinicians Society securing a certificate in Medical Cannabis Explained. She is a member of PLEA’s (Patient-Led Engagement for Access) advisory board, has hosted several webinars on cannabis and women's health and has moderated at industry events such as Cannabis Europa. Sarah Sinclair is the editor of Cannabis Health. Got a story? Email sarah@handwmedia.co.uk / Follow us on Twitter: @CannabisHNews / Instagram: @cannabishealthmag

Trending

Cannabis Health is a journalist-led news site. Any views expressed by interviewees or commentators do not reflect our own. All content on this site is intended for educational purposes, please seek professional medical advice if you are concerned about any of the issues raised.

Copyright © 2023 PP Intelligence Ltd.